Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc. (CSI) is devoted to developing and commercializing innovative solutions for treating peripheral and coronary artery disease. Our primary focus is helping physicians conquer even the most difficult disease states, including calcium, given the complications it presents for the millions who suffer from peripheral artery disease (PAD) and coronary artery disease (CAD). CSI is committed to clinical rigor, constant innovation, and a defining drive to set the standard in safe and effective medical devices to help improve patient outcomes. We have developed patented orbital atherectomy systems (OAS) technology for both peripheral and coronary commercial applications.Our peripheral artery disease (PAD) systems are catheter-based platforms capable of treating a broad range of plaque types in leg arteries both above and below the knee and address many of the limitations associated with other treatment alternatives.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical Equipment
- Market Focus:
- Globally (various continents)
- Employees:
- 101-1000
We Are
Protecting Our Employees
CSI is taking responsibility to serve physicians and patients in need and we are following the recommendations from the Centers for Disease Control and the World Health Organization, as well as State and Local Hospital requirements to prioritize safety, protect our employees and to best protect healthcare teams who are treating patients around the world. We have provided each of our employees with personal protective equipment (if it is preferred or beneficial for hospitals/clinics to conserve their own supply).
Commitment to Our Customers
CSI remains committed to providing the important medical devices that help our physicians treat challenging patient populations and we stand ready to support you in your general practice and in the care of your more severe cases that cannot be postponed. Our field employees are ready to work with you to identify solutions in case support, whether remotely or in person, given your hospital/clinic needs.
Uninterrupted Supply Chain
Our orbital atherectomy devices are manufactured in the United States at our Minnesota and Texas facilities and production is continuing as usual. In addition, we do not anticipate any disruptions in our supply chain for OrbusNeich distributed products like the Sapphire® angioplasty balloons and Teleport® Microcatheters.
We will continue to monitor developments related to the COVID-19 outbreak and will provide updates if our circumstances change.
Our coronary product is a catheter-based platform ...
Our coronary product is a catheter-based platform designed to facilitate stent delivery in patients with coronary artery disease (CAD) who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to de novo, severely calcified coronary artery lesions. The Coronary OAS design is similar to technology used in our Peripheral OAS, customized specifically for the coronary application.
Vision
To treat the symptoms of cardiovascular disease as a barrier to living a full life by providing awareness, education and innovation.
LEADING THE WAY TO HELP TREAT ARTERIAL CALCIUM
COMMITTED TO GETTING PEOPLE WITH PAD AND CAD BACK TO WHAT MATTERS
COLLABORATING WITH LEADING EXPERTS
Our Mission
Saving Limbs. Saving Lives. Every Day. As the market leader in both peripheral and coronary atherectomy, Cardiovascular Systems, Inc. (CSI), based in St. Paul, Minnesota, is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. In a few minutes of treatment time, our Diamondback 360® Orbital Atherectomy Systems treat calcified and fibrotic plaque in arteries throughout the leg and heart, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. The patient populations we serve are large and growing. We have demonstrated that our unique mechanism of action can effectively treat patients suffering from calcified arterial disease. We are committed to developing innovative enhancements to improve the quality of care and expand the number of patients with coronary artery disease (CAD) and peripheral artery disease (PAD) that can be treated with our products.
The following materials and resources are made available to individuals or members of the media to serve as background information on CSI’s products and the disease states we treat.